With COVID Crash In Sight, Moderna’s Post-Pandemic Future Starts To Take Shape
The company reported a fourth quarter decline in SARS-CoV-2 vaccine sales and guided for sales of $5bn in 2023. It is looking ahead to filing for approval of its RSV vaccine.
You may also be interested in...
The company had its fourth vaccines day, where it talked about its strategy over the next few years for vaccines against COVID-19, RSV, flu and combinations thereof.
Stéphane Bancel also gave conflicting answers for how the company set the cost of its mRNA COVID-19 vaccine as Democratic lawmakers tried to berate Moderna for its coming price hikes. Republicans lawmakers argue against retroactive shaming, saying that if the government wanted to set the eventual commercial price, it should have done that early in negotiations.
The company aims to deliver DNA via lipid nanoparticles as well as delivering LNPs systemically to tissues beyond the liver and spleen, which the CEO called a “frontier” in an interview.